Hol dir die App Get the App
⭐️⭐️⭐️⭐️⭐️
44 Bewertungen
Zur App
DAX 26.458,50 0,19% Dow Jones 53.715,50 -0,27% MDAX 32.496,90 0,40% Nikkei 225 68.623,30 -0,68% S&P 500 7.782,88 -0,23% STOXX Europe 50 6.545,00 -0,27% Nasdaq 100 30.026,10 -0,20% Bitcoin 63.010,99 USD 0,28% Gold 140,71 USD 0,02% EUR/USD 1,16 USD 0,33%
DAX 26.458,50 0,19% Dow Jones 53.715,50 -0,27% MDAX 32.496,90 0,40% Nikkei 225 68.623,30 -0,68% S&P 500 7.782,88 -0,23% STOXX Europe 50 6.545,00 -0,27% Nasdaq 100 30.026,10 -0,20% Bitcoin 63.010,99 USD 0,28% Gold 140,71 USD 0,02% EUR/USD 1,16 USD 0,33%
+49 (0) 172 414 333 6

63,82 €

  • 0,00 €
  • |
  • 0,00 %

Your browser does not support the canvas element.

  • 2013
  • 2015
  • 2016
  • 2018
  • 2020
  • 2022
  • 2024
  • 2026
  • 0
  • 50
  • 150
  • 200
  • 250

ERTRÄGE

Warnung: Die Dividende wurde um 73,5% gekürzt auf 0,45 € pro Aktie. Dies könnte eine strategische Entscheidung sein oder auf veränderte finanzielle Prioritäten hinweisen. Aktionäre sollten prüfen, ob dies ein isolierter Rückschlag oder ein Zeichen struktureller Probleme ist.

0,45 €

Jährliche Dividende

0,70 %

Rendite

  • 0,42 €

    Apr.
  • 0,42 €

    Juli
  • 0,42 €

    Okt.
  • 0,45 €

    Jan.

-73,50 %

Dividenden-Wachstum

  • 17

  • 18

  • 19

  • 20

  • 21

  • 22

  • 23

  • 24

  • 25

  • 26

29,10 %

Ausschüttungsquote

  • A

    29 %
  • 71 %

    G

  • A

    26 %
  • 74 %

    OCF

Historische Dividenden

    • 0,00 %
    • 0,00 €
    2019
    • 0,55 %
    • 0,68 €
    2020
    • 0,56 %
    • 0,85 €
    2021
    • 0,65 %
    • 1,10 €
    2022
    • 0,84 %
    • 1,27 €
    2023
    • 0,91 %
    • 1,46 €
    2024
    • 1,26 %
    • 1,69 €
    2025
    • 0,42 %
    • 0,45 €
    2026

UNTERNEHMEN

9,4 Mrd. $

Umsatz

  • 2,7 Mrd.

    NG

  • 685,0 Mio.

    F&E

  • 6,7 Mrd.

    BG

  • 9,4 Mrd.

    U

1,52 %

Umsatz-Wachstum

  • 22

  • 23

  • 24

  • 25

  • 26

2,7 Mrd. $

Nettogewinn

  • 53,6 %

    ROE
  • 28,2 %

    ROS
  • 18,3 %

    ROA
  • 43,1 %

    GPM

2,9 Mrd. $

Operativer Cashflow

  • FCF

    77 %
  • 23 %

    CapEx

5,0 Mrd. $

Eigenkapital

  • EK 34 %
  • 66 % FK

13.800

Mitarbeiter

  • 680.942,0 $

    Umsatz / MA
  • 192.101,4 $

    Gewinn / MA

KGV

24,02 $

KBV

12,88 $

KCV

28,46 $

KUV

6,78 $

EV/EBITDA

17,67 $

EV/EBIT

20,22 $

EV/FCF

31,91 $

EV/Umsatz

7,61 $

EnterpriseValue

71,5 Mrd. $

Eigenkapitalrendite

53,56 %

Umsatzrendite

28,21 %

EBIT-Marge

37,63 %

EBITDA-Marge

43,06 %

Kapitalumschlag

0,65 $

Gesamtkapitalrendite

18,29 %

Eigenkapitalquote

0,34 $

Fremdkapitalquote

0,66 $

Verschuldungsgrad

1,93 $

Dyn. Verschuldungsgrad

3,27 $

Sachinvestitionsquote

-0,23 $

Anlagendeckungsgrad 1

1,70 $

Anlagendeckungsgrad 2

0,73 $

Liquidität 1. Grades

0,60 $

Liquidität 2. Grades

1,08 $

Liquidität 3. Grades

2,04 $

Dividende pro Aktie

1,73 $

Dividendenrendite

1,21 %

Ausschüttungsquote

29,10 %

Buchwert pro Aktie

11,08 $

Cashflow pro Aktie

6,52 $
Stand: 30.09.2025 TTM

CEO

Kristin Peck

Kristin Peck, geboren am 12. Februar 1971 in New York City, ist seit dem 1. Januar 2020 Chief Executive Officer von Zoetis Inc. Sie hat einen Bachelor of Arts in Economics von der Georgetown University und einen MBA von der Columbia Business School. Peck trat 2010 in das Unternehmen ein. Ihr Vermögen wird auf 40 Millionen USD geschätzt. Peck besitzt Anteile an Zoetis.
Kristin Peck, geboren am 12. Februar 1971 in New York City, ist seit dem 1. Januar 2020 Chief Executive Officer von Zoetis Inc. Sie hat einen Bachelor of Arts in Economics von der Georgetown University und einen MBA von der Columbia Business School. Peck trat 2010 in das Unternehmen ein. Ihr Vermögen wird auf 40 Millionen USD geschätzt. Peck besitzt Anteile an Zoetis.

Fakten

  • Sitz

    USA

  • Hauptsitz

    Parsippany

  • Börsengang

    01.02.2013

  • Ausstehende Aktien

    446,95 Mio.

  • Mitarbeiter

    13,80 Tsd.

  • Währung

    USD

  • Sektor

    Gesundheitswesen

  • Industrie

    Drug Manufacturers - General

  • Börse

    NYSE

  • Ticker

    ZTS

  • Webseite

    zoetis.com

Aktie

Unternehmensinfos

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, refe...
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.